Keytruda biosimilars are moving closer to market, with the FDA already accepting Formycon’s FYB206 and indicating a possible approval as early as the third quarter of 2027. While the regulatory path is opening, the market may still resist uptake as branded manufacturers leverage pharmacy benefit manager and other contracting dynamics—creating hurdles for rapid price competition.